IL6 and chronic kidney disease: In the Trial to Evaluate Reduction in Inflammation in Patients with Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition (RESCUE), Ziltivekimab, a monoclonal antibody inhibiting the IL-6 ligand, markedly reduced the serum biomarkers of inflammation and thrombosis in patients with advanced chronic kidney disease [116].